ReviewCell biochemistry and biophysics2026
Galectin-3 as a Key Driver of Neuroinflammation and α-Synuclein Aggregation in Parkinson's Disease: Unlocking New Paths for Biomarkers and Therapies.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder, characterized by dopaminergic neuronal loss within the substantia nigra pars compacta (SNpc). The gradual progression of neuronal loss results in a significant decline in dopamine levels in the striatum, leading to several hallmarks of motor complications, including resting tremors, rigidity, postural instability, bradykinesia, and a variety of non-motor symptoms, like cognitive decline, mood disturbances, and autonomic dysfunction, reflecting the widespread neurochemical and structural involvement beyond the nigrostriatal pathway. Galectin-3 (Gal-3), a lectin that can bind beta-galactosidase, regulates a diverse spectrum of biological processes, including cell adhesion, tissue development, wound healing, and immune response via different signalling cascades. Recent research has identified its role as a neuroinflammatory mediator in PD pathology, as it induces microglial activation and the secretion of proinflammatory cytokines. In this context, it also influences several biological mechanisms such as phagocytosis, autophagy, and lysosomal degradation, which are all essential for preserving protein homeostasis and clearing misfolded α-syn. Elevated levels of Gal-3 in the blood, cerebrospinal fluid (CSF), and brain tissue of PD patients demonstrate disease severity and progression. Recent preclinical and clinical findings suggested that inhibiting Gal-3 may reduce neuroinflammation and protect dopaminergic neurons, making it an encouraging therapeutic target in PD management. This review highlights the multifaceted role of Gal-3 in the pathophysiology and progression of PD, focusing on its involvement in neuroinflammation and neurodegeneration. Additionally, this review also explores its underdeveloped potential as a diagnostic biomarker and a therapeutic target to retard the disease progression.
Indexed as
Identifiers
41014450What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.